Peppermint raises $4.7 million seed for site billing

Peppermint's $4.7 million seed is a collections company wearing a clinical-research name. On October 8, 2026 the San Francisco firm said Moxxie had led a seed for an artificial intelligence (AI) platform that bills research sites. Having watched invoice software raise on that promise, from Cleavr's €8 million seed for invoice collection to Monk's accounts-receivable round, the nearer comparison is those products, not a patient-stipend card. The October 8 note and the live homepage do not use the same operating figures.

Who wrote the cheque

Co-founders David Freeman and VJ Thurimella met at X1, Freeman as the first business hire and Thurimella as the first engineer, Peppermint's October 8 announcement says. They say they built the payments and reconciliation stack behind the consumer credit-card business Robinhood later bought to launch its Gold Card. Homebrew, Better Tomorrow Ventures, Layout Ventures, Digital Health Venture Partners and Night Capital joined, with angel investors Benjamin Mann and Evan Moore. Pulse 2.0 reported the same total and the same lead. Neither page states a valuation.

The note says the platform reads a site's clinical trial management system (CTMS), checks visits against contracts and payment history, invoices continuously and chases collections, with no migration. Proceeds are for budget negotiation, expense management and clinical-trial analytics, a ledger Peppermint says would show health-system margins across a research portfolio.

Related:HALA raised $157 million Series B led by TPG and Sanabil

The figures that do not line up

Partners, the note says, collected revenue three times faster, cut overdue invoices threefold and reclaimed 20% of staff time spent on billing. Studies under management tripled in three months. No site is named. The live homepage lists a different quartet: a threefold reduction in days sales outstanding (DSO), a sixfold improvement in time to invoice, 25% of staff time reclaimed, and 15% of missing revenue found. The 25% is not the note's 20% of billing time, and the other three lines are absent from the October 8 text. This piece does not adopt the larger staff-time figure. The dated note is the one attached to the round.

Sites are on. Hospitals are marked coming soon

Clinical research sites, site management organisations and networks are marked active. Peppermint will run billing end to end, or sit behind a site's own billers. Contract research organisations (CROs), sponsors, hospital systems and academic medical centres are labelled coming soon, so the note's demand from hospital systems is not a live hospital product. Citing a 2024 survey by the Society for Clinical Research Sites (SCRS), Peppermint says one-third of sites have more than 90 days of overdue receivables, and that 50% have three months or less of operating capital. Scout Clinical's June 23, 2025 write-up states both figures. The note links an SCRS guides index, not a data table, so the percentages travel as Peppermint's citation, repeated by Scout.

Peppermint says it operates under the Health Insurance Portability and Accountability Act (HIPAA), with System and Organization Controls (SOC) 2 certification in progress. Onboarding, it says, takes about a week for most sites.

Incumbents already sell the other side

Nothing opened for this piece shows a comment from Suvoda, or from Scout, on the round. In an October 23, 2025 note, Associate Vice President Ashley Leuthe described Greenphire Site Payments, now on the Suvoda platform after the merger, as sponsor-and-site workflow across nearly 80 countries and more than 200 markets, with study-record links that create payments and invoices. Greenphire Patient Payments handles participant stipends. Scout's write-up does not mention Peppermint. Neither Greenphire product is a site's accounts-receivable (AR) book.

Sponsor-side payments move money a sponsor has already scheduled. Peppermint is selling the reconstruction of what a site believes it is owed, then the chase, nearer the accounts-receivable agents behind Fazeshift's raise than a participant card.

"At X1 and Robinhood we helped build systems designed for precision and scale, to process billions of dollars every year," said David Freeman, co-founder of Peppermint. "We're bringing that architecture to clinical research, converting earnings into friction-free collections that also provide CROs and sponsors with cleaner data from the source."

The Business Wire text carried by Morningstar carries the same release.

"There is no standard financial infrastructure for clinical trial billing today — every dollar a site is owed has to be reconstructed by hand from disconnected systems," said Alex Roetter, managing director and general partner at Moxxie. "Peppermint is bringing the discipline of modern fintech to one of healthcare's least-examined back offices."

What has to be true next

Budget negotiation and expense management still have to ship while hospitals and sponsors are marked coming soon, and a named site still has to own the 20% billing-time claim. If the homepage's 25% and the note's 20% stay up, a finance lead cannot tell which operating result the seed bought.